IFNA1 and myeloproliferative disorder: As seen in previous MPN mouse model studies using IFNα31–33, PEG-IFNα treatment significantly reduced hematocrit (HCT) and red blood cell (RBC) levels in these mice (Supplementary Fig. 6g–j).